Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021:1342:193-232.
doi: 10.1007/978-3-030-79308-1_6.

Immuno-Oncology for Gynecologic Malignancies

Jeffrey A How  1 , Ami Patel  1 , Amir A Jazaeri  2
Affiliations
Review

Immuno-Oncology for Gynecologic Malignancies

Jeffrey A How et al. Adv Exp Med Biol. 2021.

Abstract

Patients with advanced and/or recurrent gynecologic cancers derive limited benefit from currently available cytotoxic and targeted therapies. Successes of immunotherapy in other difficult-to-treat malignancies such as metastatic melanoma and advanced lung cancer have led to intense interest in clinical testing of these treatments in patients with gynecologic cancers. Currently, in the realm of gynecologic oncology, the FDA-approved use of immune checkpoint inhibitors is limited to microsatellite instability-high cancers, cancers with high tumor mutational burden, and PD-L1-positive cervical cancer. However, there has been an exponential growth of clinical trials testing immunotherapy approaches both alone and in combination with chemotherapy and/or targeted agents in patients with gynecologic cancers. This chapter will review some of the major reported and ongoing immunotherapy clinical trials in patients with endometrial, cervical, and epithelial ovarian cancer.

Keywords: Adoptive cell transfer; Cancer vaccines; Cervical cancer; Endometrial cancer; Immune checkpoint inhibitors; Immunotherapy; Ovarian cancer.

PubMed Disclaimer

References

    1. Dellinger, T. H., & Monk, B. J. (2009). Systemic therapy for recurrent endometrial cancer: A review of North American trials. Expert Review of Anticancer Therapy, 9(7), 905–916. - PubMed
    1. Liontos, M., et al. (2019). Systemic therapy in cervical cancer: 30 years in review. Critical Reviews in Oncology/Hematology, 137, 9–17. - PubMed
    1. Armbruster, S., Coleman, R. L., & Rauh-Hain, J. A. (2018). Management and treatment of recurrent epithelial ovarian cancer. Hematology/Oncology Clinics of North America, 32(6), 965–982. - PubMed
    1. Hodi, F. S., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711–723. - PubMed - PMC
    1. Topalian, S. L., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine, 366(26), 2443–2454. - PubMed - PMC

LinkOut - more resources